Laronidase
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I
Trial Timeline
Oct 28, 2021 → Jul 26, 2023
NCT ID
NCT05134571About Laronidase
Laronidase is a approved stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT05134571. Target conditions include Mucopolysaccharidosis I.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05134571 | Approved | Completed |
| NCT00418821 | Approved | Terminated |
| NCT00144768 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I